Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer

Journal of Immunology

Volumn 182, Issue 12, 2009, Pages 7548-7557

  Eruslanov, Evgeniy ^a   Kaliberov, Sergei ^b   Daurkin, Irina ^a   Kaliberova, Lyudmila ^b   Buchsbaum, Donald ^b   Vieweg, Johannes ^a   Kusmartsev, Sergei ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ADENOVIRUS VECTOR; APC PROTEIN; CD11B ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTAGLANDIN E2; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; BONE MARROW CELL; CANCER INFILTRATION; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; ERADICATION THERAPY; FEMALE; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ADENOVIRUS; ANIMAL; ANTIGEN PRESENTING CELL; CANCER TRANSPLANTATION; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; LYMPH NODE; METABOLISM; NEOPLASM; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE; TUMOR ESCAPE;

ADENOVIRIDAE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11B; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; LYMPH NODES; MALE; MICE; MYELOID CELLS; NEOPLASM TRANSPLANTATION; NEOPLASMS; SURVIVAL RATE; TUMOR ESCAPE;

EID: 67649232608     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802358     Document Type: Article

References (50)

1. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 253-274.
2. Ostrand-Rosenberg, S. 2008. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 18: 11-18.
3. Gabrilovich, D. 2004. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4: 941-955.
4. Steinman, R. M., and J. Banchereau. 2007. Taking dendritic cells into medicine. Nature 449: 419-426.
5. Vieweg, J., Z. Su, P. Dahm, and S. Kusmartsev. 2007. Reversal of tumor-induced immune suppression. Clin. Cancer Res. 13: 727-732.
6. Wang, D., and R. N. Dubois. 2006. Prostaglandins and cancer. Gut 55: 115-122.
7. Dannenberg, A., and K. Subbaramaiah. 2003. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436.
8. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. P. Portanova, J. C. Lee, and S. M. Dubinett. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164: 361-370.
9. Yang, L., N. Yamagata, R. Yadav, S. Brandon, R. L. Courtney, J. D. Morrow, Y. Shyr, M. Boothby, S. Joyce, D. P. Carbone, and R. M. Breyer. 2003. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. 111: 727-735.
10. Rodriguez, P. C., C. P. Hernandez, D. David Quiceno, S. M. Dubinett, J. Zabaleta, J. B. Ochoa, G. Gilbert, and A. C. Ochoa. 2005. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J. Exp. Med. 202: 931-939.
11. Sinha, P., V. K. Clements, A. M. Fulton, and S. Ostrand-Rosenberg. 2007. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 67: 4507-4513.
12. Sombroek, C. C., A. G. M. Stam, A. J. Masterson, S. M. Lougheed, M. J. A. G. Schakel, C. J. L. M. Meijer, H. M. Pinedo, A. J. M. van den Eertwegh, R. J. Scheper, and T. D. de Gruijl. 2002. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168: 4333-4343.
13. Sharma, S., L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, R. Batra, and S. M. Dubinett. 2005. Cyclooxygenase 2 inhibition promotes IFN-γ-dependent enhancement of anti-tumor responses. J. Immunol. 175: 813-819.
14. DeLong, P., T. Tanaka, R. Kruklitis, A. C. Henry, V. Kapoor, L. R. Kaiser, D. H. Sterman, and S. M. Albelda. 2003. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63: 7845-7852. (Pubitemid 37466718)
15. Haas, A. R., J. Sun, A. Vachani, A. F. Wallace, M. Silverberg, V. Kapoor, and S. M. Albelda. 2006. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin. Cancer Res. 12: 214-222.
16. Dowd, N. P., M. Scully, S. R. Adderley, A. J. Cunningham, and D. J. Fitzgerald. 2001. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J. Clin. Invest. 108: 585-590.
17. Levesque, L. E., J. M. Brophy, and B. Zhang. 2005. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults Ann. Intern. Med. 142: 481-489. (Pubitemid 40490913)
18. Ensor, C. M., and H. H. Tai. 1995. 15-Hydroxyprostaglandin dehydrogenase. J. Lipid Mediators Cell Signal. 12: 313-319.
19. +-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des. 12: 955-962.
20. 4 12-hydroxydehydrogenase in inflammation. J. Biol. Chem. 275: 25372-25380.
21. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26: 65-72.
22. Myung, S. J., R. M. Rerko, M. Yan, P. Platzer, K. Guda, A. Dotson, E. Lawrence, A. J. Dannenberg, A. K. Lovgren, G. Luo, et al. 2006. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. USA 103: 12098-12102.
23. Wolf, I., J. O'Kelly, T. Rubinek, M. Tong, A. Nguyen, B. T. Lin, H.-H. Tai, B. Y. Karlan, and H. P. Koeffler. 2006. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66: 7818-7823.
24. Backlund, M. G., J. R. Mann, V. R. Holla, F. G. Buchanan, H. H. Tai, E. S. Musiek, G. L. Milne, S. Katkuri, and R. N. DuBois. 2005. 15- Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J. Biol. Chem. 280: 3217-3223.
25. Tong, M., Y. Ding, and H. H. Tai. 2006. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. Carcinogenesis 27: 2170-2179. (Pubitemid 44644805)
26. Ferrara, N., and R. S. Kerbel. 2005. Angiogenesis as a therapeutic target. Nature 438: 967-974.
27. Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
28. Grunewald, M., I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Yung, S. Chimenti, L. Landsman, R. Abramovitch, and E. Keshet. 2006. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175-189.
29. Kaliberov, S. A., L. N. Kaliberova, C. R. Stockard, W. E. Grizzle, and D. J. Buchsbaum. 2004. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. Mol. Ther. 10: 1059-1070.
30. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 co-stimulation J. Immunol. 165: 779-785.
31. Kusmartsev, S., and D. Gabrilovich. 2006. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55: 237-245.
32. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166.
33. Harizi, H., M. Juzan, V. Pitard, J.-F. Moreau, and G. N. 2002. Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168: 2255-2263.
34. + T regulatory cell activities in lung cancer. Cancer Res. 65: 5211-5220.
35. +-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-α. Am. J. Physiol. 290: G361-G368.
36. + T cells. J. Clin. Invest. 116: 2777-2790.
37. Sinha, P., V. K. Clements, and S. Ostrand-Rosenberg. 2005. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65: 11743-11751.
38. Van Ginderachter, J. A., S. Meerschaut, Y. Liu, L. Brys, K. De Groeve, G. H. Ghassabeh, G. Raes, and P. De Baetselier. 2006. Peroxisome proliferator-activated receptor γ(PPARγ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 108: 525-533.
39. Pollard, J. 2004. Tumour-educated macrophages promote tumour progression and metastasis Nat. Rev. Cancer 4: 71-78. (Pubitemid 38082155)
40. Mattes, J., M. Hulett, W. Xie, S. Hogan, M. E. Rothenberg, P. Foster, and C. Parish. 2003. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197: 387-393.
41. Gerber, H.-P., F. Condorelli, J. Park, and N. Ferrara. 1997. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes: Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272: 23659-23667.
42. Kusmartsev, S., E. Eruslanov, H. Kübler, A. Heiser, I. Sakai, A. Su Z, C. Rosser, P. Dahm, D. Siemann, and J. Vieweg. 2008. Oxidative stress up-regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 181: 346-353.
43. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290.
44. Mantovani, A., T. Schioppa, C. Porta, P. Allavena, and A. Antonio Sica. 2006. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25: 315-322.
45. + immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J. Immunol. 175: 8200-8208.
46. Zhang, B., N. B. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y.-X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204: 49-55.
47. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. Delgado, P. Correa, J. Brayer, E. M. Sotomayor, et al. 2004. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits Tcell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 5839-5849.
48. Kusmartsev, S., and D. Gabrilovich. 2005. STAT1 signaling regulates tumorassociated macrophage-mediated T cell deletion. J. Immunol. 174: 4880-4891. (Pubitemid 40504572)
49. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
50. + myeloid cells that promote metastasis. Cancer Cell 13: 23-35.